Table 1

Demographics and disease characteristics of patients at baseline

Full cohort
N (%)
PDL1 known group
N (%)
Age
 ≥6592 (57)70 (61)
 <6569 (43)44 (39)
Sex
 M90 (56)66 (58)
 F71 (44)48 (42)
ECOG
 ≤1137 (85)96 (84)
 >123 (14)17 (15)
 Unknown2 (1)1 (1)
Smoking
 Yes131 (81)91 (80)
 No19 (12)14 (12)
 Unknown11 (7)9 (8)
Histopathology
 Adenocarcinoma106 (66)74 (65)
 SCC45 (28)32 (28)
 Others10 (6)8 (7)
Molecular status*
 KRAS mutant55 (47)41 (50)
 KRAS wild type46 (40)36 (44)
 KRAS unknown10 (9)2 (2)
 EGFR, ALK or ROS1 mutant5 (4)3 (4)
Line of treatment
 First line37 (23)37 (32)
 Second or more124 (77)77 (68)
Total161114
  • *Molecular status was only examined in NSCLC with non-squamous cell carcinoma histology (116 patients in full cohort and 82 in the PDL1 known group).

  • ALK, echinoderm microtubule-associated protein like-4-anaplastic lymphoma kinase (EML4/ALK) fusion; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; KRAS, Kirsten Rat Sarcoma GTPase; NSCLC, non-small cell lung cancer; PDL1, programmed death ligand; ROS1, echinoderm c-ros oncogene 1 fusion; SCC, squamous cell carcinoma.